Previous 10 | Next 10 |
BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the NEURO-TTR open-label extension study and the clinical impac...
Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi...
Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Michael Ma...
Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n...
Akcea Therapeutics (NASDAQ: AKCA ) Q1 results ($M): Revenues: 163.8 (+857.9%) due to a $150M license fee from Novartis for AKCEA-APO(a)-Lrx. More news on: Akcea Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Akcea Therapeutics (NASDAQ: AKCA ): Q1 Non-GAAP net income of $45.7M. More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Achieved First Quarter 2019 TEGSEDI ® (inotersen) Global Net Product Revenues of $7 Million Novartis exercised its option to license AKCEA-APO(a)-L Rx Received marketing authorization for WAYLIVRA ® (volanesorsen) in E.U. Confer...
AAOI , AIMT , AKCA , ALB , ANGI , APLE , ARNA , ASRT , AXGN , BIO , BREW , CCMP , CECO , CNDT , COLL , CPA , CTL , CVNA , CW , CWH , CXW , DAR , DHT , DIS , DRH , DVAX , ECPG , EGAN , ELF , ENV , ET , ETSY , EVRG , EZPW , FLNT , FNV , FOSL , FOXA , FTK...
Akcea Therapeutics (NASDAQ: AKCA ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after market close. The consensus EPS Estimate is $0.98 and the consensus Revenue Estimate is $171.4M (+901.8% Y/Y). Over the last 1 year, akca has beaten EPS estimates 25% of ...
NEURO-TTR phase 3 open-label extension study showed TEGSEDI ® ( inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy Greater efficacy and clinical benefit observed with early initiation of TEG...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...